Initial test analyte Marijuana metabolites (THCA)2 Cocaine metabolite (Benzoylecgonine). Codeine/Morphine Hydrocodone/Hydromorphone Oxycodone/Oxymorphone


6-Acetylmorphine Phencyclidine


Amphetamine/Methamphetamine MDMA4 /MDA5


Initial test cutoff


50 ng/mL3 150 ng/mL3


2,000 ng/mL 300 ng/mL 100 ng/mL


10 ng/mL 25 ng/mL


500 ng/mL 500 ng/mL


provide a sufficient urine specimen at the collection facility. In addition, in situations of a canceled or invalid urine specimen test, the MRO is directed to recommend that the agency collect another specimen using oral fluids. Collection sites are urged to monitor collectors closely with regard to this, as some collectors may be tempted to use oral to complete the test faster.1


Marijuana and Explanations for a Positive Drug Test Result Te Department also noted in the guidelines that passive exposure to marijuana smoke, as well as the ingestion of food products containing marijuana, are not acceptable medical explanations for a positive drug test result. According to the Department, individuals who are passively exposed to marijuana smoke or who consume food products containing marijuana can pose public safety and/or security risks.


Confirmatory test analyte THCA Benzoylecgonine


Codeine Morphine


Hydrocodone Hydromorphone


Oxycodone Oxymorphone


6-Acetylmorphine Phencyclidine


Amphetamine Methamphetamine


MDMA MDA


Fatal Flaws Te Department has added three new fatal flaws to the mandatory guidelines, of which all service agents must be aware. Tese are: 1. Te specimen was received at the HHS lab without a CCF;


2. Te CCF was received at the HHS lab without a specimen; and


3. Te collector performed two separate collections using one CCF.


In addition, HHS revised the fatal flaw


section to include an additional item to allow a laboratory or Instrumental Initial Test Facility (IITF) to reject a specimen when they identify a flaw that prevents testing or affects the forensic defensibility of the drug test, and cannot be corrected. Tis general item enables laboratories and IITFs to reject specimens with fatal flaws that may be rare, but do occur. Te Final HHS Mandatory Guidelines


for Federal Workplace Drug Testing Programs takes effect on October 1, 2017. Until then, service agents should prepare their clients for compliance. ❚


Reference


The HHS guidelines with procedures on how to collect and test oral fluid specimens have not yet been published. In order for oral fluid specimens to be authorized by HHS effective October 1, 2017, such procedures must be published first.


Dean Klassy is the Drug Test- ing Program Administrator for Sandia National Laboratories in Albuquerque, NM. He man- ages over 12,000 employees who are covered by the


Department of Energy (DOE), which follows the HHS guidelines. Prior to his current posi- tion, he operated a full-service consortium in Wisconsin for 23 years, providing complete consortium services to companies around the county. Dean is a Charter Member of DATIA and served as Chairman of the Board of Directors for eight years. He currently serves on two committees for DATIA and has been the author or co-author of the Consortium Management Programs for DATIA. Dean is currently the National Instructor for the Con- sortia/Third Party Administrator Best Practice. He is also a DATIA R-CPCT and C-DER and a Certified MRO Assistant by MROCC.


Confirmatory test cutoff concentration


15 ng/mL. 100 ng/mL.


2,000 ng/mL. 2,000 ng/mL.


100 ng/mL. 100 ng/mL.


100 ng/mL. 100 ng/mL.


10 ng/mL. 25 ng/mL.


250 ng/mL. 250 ng/mL.


250 ng/mL. 250 ng/mL.


42


datia focus


summer 2017


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60